Bolt Biotherapeutics, Inc. (BOLT) stock
BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/305% above fair value
$5.65−0.15 (-2.59%)
Close on Nov 17, 2026Market cap $10.88MP/E –Yield –
Bolt Biotherapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Bolt Biotherapeutics's price to book ratio was 1.0× on Nov 11, 2026, against 0.3× a year earlier. Over the last 5 years it ranged from 0.2× to 1.0×, with a median of 0.3×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.0× | +0.6 |
| 2025 | Dec 31, 2025 | 0.3× | +0.0 |
| 2024 | Dec 31, 2024 | 0.3× | −0.0 |
| 2023 | Dec 29, 2023 | 0.3× | +0.1 |
| 2022 | Dec 30, 2022 | 0.3× | −0.4 |
| 2021 | Dec 31, 2021 | 0.7× | – |
See a number that looks wrong?